MAPT and Alzheimer disease: Substantial studies and clinical trials have demonstrated that it is difficult to develop one medicine for the treatment of AD, because the pathogenesis is very complex, including neurochemicals, amyloid and tau pathological processes, mitochondria, inflammatory pathways and neuroglia [6].